TherapeuticsMD, Inc. (TXMD) — Financial statements
Income statement, balance sheet, and cash flow for TherapeuticsMD, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3↑71.6% | 2↑35.3% | 1↓98.1% | 70↑2619.1% | 3 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 1↓0.4% | 1 | |
| Gross Profit | 3↑71.6% | 2↑35.3% | 1↓98.1% | 69↑5755.3% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 7 | 0.00 | 0.00↓100.0% | 58↓20.4% | 73 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00↑100.0% | -1 | 0.00 | |
| SG&A Expenses | 7 | 0.00 | 0.00↓100.0% | 57↓22.0% | 73 | |
| Other Expenses | 0.38↓94.1% | 7↓33.6% | 10↓7.9% | 11↑33.3% | 8 | |
| Operating Expenses | 7↑11.0% | 7↓33.6% | 10↓85.4% | 67↓16.6% | 81 | |
| Total Costs & Expenses | 7↑11.0% | 7↓33.6% | 10↓85.7% | 69↓16.3% | 82 | |
| Operating Results | ||||||
| Operating Income | -4↑11.5% | -5↑44.2% | -9↓815.6% | 1↑101.5% | -80 | |
| Depreciation & Amortization | 1↑134.4% | 0.51↑16.1% | 0.44↓63.5% | 1↑63.0% | 0.74 | |
| EBITDA | -3↓1.3% | -3↑63.1% | -8↓168.1% | 12↑116.7% | -71 | |
| EBIT | -4↓20.7% | -3↑59.0% | -9↓179.9% | 11↑114.9% | -72 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.14↑4.9% | 0.14 | 0.00 | 0.00↑100.0% | -33 | |
| Interest Income | 0.14↓2.0% | 0.14 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.01 | 0.00 | 0.00↓100.0% | 33 | |
| Non-Operating Income | 0.00↑100.0% | -1 | 0.00↑100.0% | -9↓18.4% | -8 | |
| Other Income / Expenses | 4↑47.3% | 2↑209.5% | 0.78↑767.5% | -0.12↓143.0% | 0.27 | |
| Income Before Tax | -0.65↑72.1% | -2↑69.7% | -8↓820.9% | 1↑101.4% | -79 | |
| Income Tax Expense | 0.00↑100.0% | -0.03↑27.9% | -0.04 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -0.65↑71.8% | -2↑70.0% | -8↓816.9% | 1↑101.4% | -79 | |
| Net Income from Discontinued Operations | 0.08↓35.9% | 0.13↑105.1% | -3↓102.3% | 111↑219.1% | -93 | |
| Net Income | -0.57↑73.9% | -2↑78.8% | -10↓109.2% | 112↑165.0% | -172 | |
| Bottom-Line Net Income | -0.57↑75.4% | -2↑70.0% | -8↓106.9% | 112↑241.2% | -79 | |
| EPS (Basic) | -0.05↑74.1% | -0.19↑65.5% | -0.55↑94.7% | -10.35↑59.9% | -25.83 | |
| EPS (Diluted) | -0.05↑74.1% | -0.19↑74.3% | -0.74↑92.9% | -10.35↑59.9% | -25.83 | |
| Weighted Average Shares | 12↑0.3% | 12↑10.4% | 10↑15.7% | 9↑13.4% | 8 | |
| Weighted Average Diluted Shares | 12↑0.3% | 12↑10.4% | 10↑15.7% | 9↑13.4% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.